Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1630]

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural...

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

PARP inhibitors for metastatic breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

KATHERINE trial updates for HER2-positive breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...

Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )

Precision medicine in ALK-positive NSCLC: Results from the BFAST trial

Prof Solange Peters and Prof Tony Mok

Precision medicine in ALK-positive NSCLC: Results from the BFAST trial ( Prof Solange Peters and Prof Tony Mok )

Latest developments in metastatic prostate cancer from ESMO 2019

Prof Nick James and Prof Nicholas Mottet

Latest developments in metastatic prostate cancer from ESMO 2019 ( Prof Nick James and Prof Nicholas Mottet )

Role of biomarkers, targeted therapy and tumour mutations in the landscape of...

Prof Petros Grivas and Dr Michiel Van der Heijden

Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer ( Prof Petros Grivas and Dr Michiel Van der Heijden )

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

PLEIADES: Daratumumab combinations for multiple myeloma

Dr Ajai Chari - Mount Sinai, New York City, USA

PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )

Impact of cancer prevention campaigns in Brazil: A google trends analysis

Dr Fernando Quintanilha - Universidade Salvador, Laureate Universities...

Impact of cancer prevention campaigns in Brazil: A google trends analysis ( Dr Fernando Quintanilha - Universidade Salvador, Laureate Universities, Salvador, Brazil )

More from ecancer